23:07 , Aug 15, 2019 |  BC Innovations  |  Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
00:16 , Jul 26, 2019 |  BC Innovations  |  Translation in Brief

GI infection as Parkinson’s trigger

A Canadian team has shown how bacterial GI infections can trigger Parkinson's disease in genetically susceptible individuals. The findings add to mounting evidence implicating the gut microbiome in CNS disorders including autism, Alzheimer's disease and...
00:38 , Jul 19, 2019 |  BC Innovations  |  Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

Two years in, GammaDelta says the $100 million Takeda option deal it signed months after launching gave the company a boost that would have been hard to come by any other way. Build-to-buy deal structures...
16:37 , Jul 18, 2019 |  BC Innovations  |  Distillery Therapeutics

Great ape-derived adenovirus vaccines from Nouscom for colorectal cancer

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Vaccination with neoantigen-encoding adenoviruses derived from great apes could help treat colorectal cancer. The neoantigens were identified by analyzing predicted MHC I and MHC II binding affinity, mutation allele...
23:26 , Jun 21, 2019 |  BC Extra  |  Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

AnaptysBio agonizes PD-1 for inflammatory disease  AnaptysBio Inc. (NASDAQ:ANAB) presented what CEO Hamza Suria called “the first data from anyone on a PD-1 agonist mAb” at the 2019 Federation of Clinical Immunology Societies (FOCiS) meeting...
20:01 , Jun 20, 2019 |  BC Innovations  |  Translation in Brief

Turning Tregs against cancer

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint...
00:28 , Jun 20, 2019 |  BC Innovations  |  Distillery Therapeutics

MHCII nanoparticles for autoimmune hepatic diseases

DISEASE CATEGORY: Hepatic INDICATION: Cirrhosis; hepatitis; liver disease A team led by Parvus Therapeutics Inc. founder Pere Santamaria has developed nanoparticles coated with MHCII molecules displaying a PDH-derived epitope associated with primary biliary cholangitis (PBC)...
20:22 , May 1, 2019 |  BC Extra  |  Preclinical News

May 1 Preclinical Quick Takes: MD Anderson, Sana, Sigilon

MD Anderson findings could make radiation possible for pancreatic cancer  Researchers at University of Texas MD Anderson Cancer Center reported findings suggesting that HIF-PH inhibition could help prevent radiation-induced GI injury, the main factor that...
13:05 , Apr 25, 2019 |  BC Extra  |  Preclinical News

Engineered Cas9 derivatives avoid T cell reactivity

Arizona State University researchers have engineered Cas9 to avoid pre-existing immunity against the bacterial protein, a safety concern for in vivo CRISPR-Cas9 gene editing. Samira Kiani, an ASU assistant professor who co-led the study, told...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...